For research and educational purposes only. Not intended for human consumption.
Mazdutide
Extensively Studied- •Phase 3 trials - 14% weight loss
- •MASH liver fat reduction data
- •Dual GLP-1/Glucagon mechanism
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Overview
What is Mazdutide?
Mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics for obesity and type 2 diabetes. It has shown up to 14% weight loss in Phase 3 trials and significant liver fat reduction in MASH studies. The dual mechanism provides synergistic effects on appetite, energy expenditure, and metabolic health.
Key Benefits
Superior weight loss through dual mechanism, significant liver fat reduction, improved glycemic control, once-weekly dosing convenience.
Mechanism of Action
Mazdutide activates both GLP-1 and glucagon receptors. GLP-1 activation reduces appetite and improves insulin secretion, while glucagon activation increases energy expenditure and promotes hepatic lipid metabolism.
Molecular Information
Pharmacokinetics
Research Indications
Severe Obesity Management
Phase 3 trials demonstrate up to 14% weight loss in obese patients.
Metabolic Syndrome
Improves multiple metabolic parameters including waist circumference.
Sustained Weight Loss
Once-weekly dosing supports long-term adherence and weight maintenance.
Research Protocols
Disclaimer: Mazdutide is in Phase 3 clinical trials and not yet FDA approved. Protocols are based on clinical trial data.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight Loss (Obesity) | 6mg weekly | Once weekly | Subcutaneous |
| Type 2 Diabetes | 3-6mg weekly | Once weekly | Subcutaneous |
| Dose Escalation | 1.5mg → 3mg → 4.5mg → 6mg | Weekly increases | Subcutaneous |
Timing: Administer same day each week. Can be given with or without food.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Pre-filled pens expected when approved
Allow to reach room temperature before injection
Inspect for particles or discoloration
Inject subcutaneously in abdomen, thigh, or upper arm
Rotate injection sites weekly
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear solution
Should be colorless and free of particles.
Not yet commercially available
Currently in Phase 3 trials.
Cloudy or discolored
Indicates degradation - do not use.
What to Expect
- •Week 1-4: GI adaptation, appetite reduction begins
- •Week 4-12: Significant weight loss acceleration
- •Week 12-24: Continued weight loss, metabolic improvements
- •Week 24+: Sustained weight management
Side Effects & Safety
Side Effects
- •Most common: nausea, vomiting, diarrhea (GI symptoms)
- •Typically mild to moderate and transient
- •Dose escalation helps minimize GI side effects
- •Contraindicated in personal/family history of medullary thyroid carcinoma
- •Not recommended during pregnancy or breastfeeding
When to Stop
- •Severe GI symptoms
- •Signs of pancreatitis
- •Allergic reactions
- •As directed by healthcare provider
References
2 StudiesGLORY-1 Phase 3 Trial
Human | 6mg weekly | 48 weeks | 14% weight loss
Pivotal obesity trial demonstrating significant weight loss vs placebo.
MASH Liver Fat Reduction Study
Human | Phase 2 | Up to 83% liver fat reduction
Showed significant hepatic steatosis improvement in MASH patients.
Quick Start Guide
Research Disclaimer
Mazdutide is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Mazdutide must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Mazdutide for any purpose. Consult qualified professionals for any research applications.